The 15th Annual Pharmacovigilance 2018 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry.
The entire program will cover the detection, analysis and prevention of adverse drug reactions. It will be studied with the help of case studies and industry experiences.
This conference will help the drug safety representatives from the pharmaceutical industry and academic and quality research organisations who wish to understand how to avoid common deficiencies in inspections by learning from the experiences of others; to gain a greater understanding of new and existing pharmacovigilance requirements, and to improve their organisations’ compliance with pharmacovigilance requirements. Also, it can help you control your product’s lifecycle, your patient’s trust, and your revenue. Hence, this conference will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting pharmacovigilance development.
– Pharmacovigilance in 2020 – future horizons and efficiencies
– Updates towards of legislation, policies, systems, technology, communication strategies and best practice in PV
– Possible effects of Brexit on Pharmacovigilance
– Strategies for best practice in bene t-risk management
– Market analysis – What is our current stand? – Moving towards the new successful PV era
– Implementing risk minimization procedures – Making sure we succeed
– Examining developments in GVP measures and status of the new Module VI
– Improving in signal management and their implications
– Latest updates and hot topics relating to the role of the QPPV
– Challenges and Opportunities to optimize the overall PV ecosystem for maximum benefit
– Safety information for signal detection and management
– Medical devices – Increasing safety perspective
– Case studies from various countries on the PV frameworks around the world
– Good Clinical Practices and Good Pharmacovigilance practices
– IT and new technologies for improvement of PV and clinical research
– Maintaining proper balance in relationships: Sponsor – Site – CRO & Patients
– Patient-centric approach to help improve patient safety
– Outsourcing activities – How to set it right?
– PV Audit & inspections – preparation, implementation and lessons to be learned
– Discover approaches for collecting, integrating and analyzing all of the safety data generated from preclinical models
– How to involve patients better to develop drugs
– The developing regulatory framework in advanced and developing markets – EU, USA & ROW
– Accelerating new medicine introduction in developing world & overcoming challenges
– Be part of a major networking opportunity